Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Aug;49(8):721-723.
doi: 10.4070/kcj.2019.0150. Epub 2019 Jun 19.

Diffuse Long Coronary Artery Disease is Still an Obstacle for Percutaneous Coronary Intervention in the Second-Generation Drug-Eluting Stent Era?

Pyung Chun Oh  1 , Seung Hwan Han  2
Affiliations
Editorial

Diffuse Long Coronary Artery Disease is Still an Obstacle for Percutaneous Coronary Intervention in the Second-Generation Drug-Eluting Stent Era?

Pyung Chun Oh et al. Korean Circ J. 2019 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors have no financial conflicts of interest.

Figures

Figure 1
Figure 1. One-year incidence of MACE or TLF after implantation of R-ZES for diffuse long coronary artery disease.
MACE = major adverse clinical event; R-ZES = Resolute™ zotarolimus-eluting stent; TLF = target lesion failure.
See this image and copyright information in PMC

Comment on

References

    1. Gwon HC, Jeon DW, Kang HJ, et al. The practice pattern of percutaneous coronary intervention in Korea: based on year 2014 cohort of Korean percutaneous coronary intervention (K-PCI) registry. Korean Circ J. 2017;47:320–327. - PMC - PubMed
    1. Bourassa MG, Lespérance J, Eastwood C, et al. Clinical, physiologic, anatomic and procedural factors predictive of restenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1991;18:368–376. - PubMed
    1. Park KH, Ahn Y, Koh YY, et al. Effectiveness and safety of zotarolimus-eluting stent (Resolute™ integrity) in patients with diffuse long coronary artery disease. Korean Circ J. 2019;49:709–720. - PMC - PubMed
    1. Taniwaki M, Stefanini GG, Silber S, et al. 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention) J Am Coll Cardiol. 2014;63:1617–1625. - PubMed
    1. Patra S, Chakraborty RN, Pande A, et al. Zotarolimus-eluting resolute integrity versus everolimus-eluting Xience Xpedition stents in the management of very long (>30mm) de novo coronary artery stenosis. Cardiovasc Revasc Med. 2017;18:160–164. - PubMed

Publication types